Evidence map›Paper›PMID 36153533›Full record

ArticleCost effectiveness and resource allocation : C/E2022

Which patients bring the most costs for hospital? A study on the cost determinants among COVID-19 patients in Iran.

Vajihe Ramezani-Doroh, Leili Tapak, Yadollah Hamidi, Saeid Bashirian, Ali Reza Soltanian, Mahyar Motaghed, Ebrahim Ghelichkhani, Elaheh Talebi-Ghane

Abstract read
In one paragraph

Article in Cost effectiveness and resource allocation : C/E, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vajihe Ramezani-DorohDepartment of Health Management and Economics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.
Leili TapakDepartment of Biostatistics, Hamadan University of Medical Sciences, Hamadan, Iran.
Yadollah HamidiDepartment of Health Management and Economics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.
Saeid BashirianSocial Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Ali Reza SoltanianDepartment of Biostatistics, Hamadan University of Medical Sciences, Hamadan, Iran.
Mahyar MotaghedFarshchian Hospital, Hamadan University of Medical Sciences, Hamadan, Iran.
Ebrahim GhelichkhaniFarshchian Hospital, Hamadan University of Medical Sciences, Hamadan, Iran.
Elaheh Talebi-GhaneModeling of Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences, PO Box: 65176-19657, Hamadan, Iran. talebi_ghane@yahoo.com.ORCID http://orcid.org/0000-0003-2610-1419

Funding

The research council of Hamadan University of Medical Sciences 9903201593
6 · The paper itself

Abstract

backgroundAccurate information on the cost determinants in the COVID-19 patients could provide policymakers a valuable planning tool for dealing with the future COVID-19 crises especially in the health systems with limited resources.

objectivesThis study aimed to determine the factors affecting direct medical cost of COVID-19 patients in Hamadan, the west of Iran.

methodsThis study considered 909 confirmed COVID-19 patients with positive real-time reverse-transcriptase polymerase-chain-reaction test which were hospitalized from 1 March to 31 January 2021 in Farshchian (Sina) hospital in Hamadan, Iran. A checklist was utilized to assess the relationship of demographic characteristics, clinical presentation, medical laboratory findings and the length of hospitalization to the direct hospitalization costs in two groups of patients (patients with hospitalization ≤ 9 days and > 9 days). Statistical analysis was performed using chi-square, median test and multivariable quantile regression model at 0.05 significance levels with Stata 14 software program.

resultsThe median cost of hospitalization in patients was totally 134.48 dollars (Range: 19.19-2397.54) and respectively 95.87 (Range: 19.19-856.63) and 507.30 dollars (Range: 68.94-2397.54) in patients with hospitalization ≤ 9 days and > 9 days. The adjusted estimates presented that in patients with 9 or less hospitalization days history of cardiovascular disease, wheezing pulmonary lung, SPO2 lower than 90%, positive CRP, LDH higher than 942 U/L, NA lower than 136 mEq/L, lymphosite lower than 20% and patients with ICU experience had significantly positive relationship to the median of cost. Moreover, in patients with more than 9 hospitalization days, history of cardiovascular disease and ICU experience was statistically positive association and age older than 60 years and WBC lower than 4.5 mg/dL had statistically negative relationship to the median of hospitalization cost.

conclusionAs the length of hospital stay, which can be associated with the severity of the disease, increases, health systems become more vulnerable in terms of resource utilization, which in turn can challenge their responsiveness and readiness to meet the specialized treatment needs of individuals.

Indexed as

CostCOVID-19IranQuantile regression

Identifiers

PMID36153533
PMCPMC9509555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.